Alnylam Pharmaceuticals, Inc. ALNYannounced new positive results from its phase I/II study on its experimental RNAi therapeutic candidate, lumasiran, which targets glycolate oxidase (GO). The data was presented at the OxalEurope, European Hyperoxaluria Consortium, in Naples, Italy.
Alnylam Reports Positive Data on Lumasiran in Renal Disease
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться